H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

LCH III is an international, multicentric, prospective clinical study comprised of:

• a randomized clinical trial for multisystem "RISK" patients and

• a randomized clinical trial for multisystem "LOW RISK" patients and

• a pilot study for patients with single system MFB and localized "SPECIAL SITES"

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of New Mexico
• Treatments: Leucovorin; Levoleucovorin; Methotrexate; Prednisone; Vinblastine

Criteria

Inclusion Criteria:

All newly diagnosed patients who meet the following criteria are eligible to be enrolled and followed in the study:

• Definitive diagnosis of LCH

• Age under 18 years

• No prior treatment for LCH

Exclusion Criteria:

• Not specified